Alzheimer's agent slows decline in mild disease.
A drug that inhibits the formation of neurotoxic amyloid-[[beta].sub.42] peptides slowed functional decline in patients with mild Alzheimer's disease by 46%, according to randomized trial findings. Patients who took the drug for 24 months fared significantly better than did those who switched to it after a year...

Disability in Alzheimer's disease: causes, consequences, and economic considerations.
ABSTRACT This literature review broadly examines disability in Alzheimer's disease (AD). The paper addresses the various types of disability in AD, as well as the presumed causes and the economic and social costs of such disability. The influence of various types of treatment of disability, particularly pharmacological...

New drug fights Alzheimer disease.
The FDA has approved a rivastigmine transdermal patch for mild to moderate Alzheimer disease. The Exelon Patch[R] (Novartis) is the first transdermal system approved to treat Alzheimer disease. The patch also has been approved for mild to moderate Parkinson disease dementia. Rivastigmine oral formulations already were approved for the...

An exploration of the marital relationship and Alzheimer's disease: one couple's story.
This article describes a qualitative single-ase study exploring the marital relationship when one spouse has been diagnosed with Alzheimer's disease (AD). The researchers used a holistic-content narrative analysis to interpret the couple's story, as it was told through three couple interviews spaced two months apart. Guided by the theoretical...

Alzheimer's disease.
ONF-06-38-I INDEPENDENT STUDY This independent study has been developed for nurses who wish to learn more about identification and treatment of Alzheimer's Disease. It takes approximately 70 minutes to complete this independent study. 1.3 contact hours will be awarded for successful completion of this independent study. ...

Healthful living may slow Alzheimer's disease.
CHICAGO -- A concerted effort to take better care of the brain with more healthful behaviors is likely to reduce the future incidence of Alzheimer's disease and may even slow disease progression in those who already have the disease, Dr. Nancy Emerson Lombardo said. Cardiovascular health and...

'Alzheimer's disease on the rise'.
PATNA: The number of patients suffering from Alzheimer's disease - a degenerative disease of the brain from which there is no recovery - in Bihar is on the rise. Stating this on the eve of "World Alzheimer's Day", Dr Diwakar Tejaswi said the disease is one of...

Digilab Announces Novel Alzheimer's Disease Biomarkers.
HANNOVER, Germany, Jan. 18 /PRNewswire/ -- Digilab, Inc. is pleased to announce a Notice of Allowance has been issued for novel Alzheimer's biomarkers discovered and identified with its proprietary Peptidomics(R) technologies. A total of 312 cerebrospinal fluid samples from patients suffering from Alzheimer's Disease, primary dementia disorder, or cognitively...

Statins may slow dementia in Alzheimer's disease.
Statin drugs may have a potential role in slowing the neurodegenerative processes involved in Alzheimer's disease, according to new evidence reported by Dr. Gail Li of the University of Washington, Seattle, and her colleagues. Dr. Samuel E. Gandy cautioned against prescribing statins widely to prevent or treat...

Neurochem announcement regarding the completion of its North American phase III clinical trial for tramiprosate (ALZHEMED(TM)) for the treatment of Alzheimer's disease.
LAVAL, QC, Feb. 1 /PRNewswire-FirstCall/ -- Neurochem Inc. announces the completion of its 18-month North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) for the treatment of Alzheimer's disease (AD). This study involved 1,052 patients, at 67 clinical sites across the United States and Canada. The drop-out rate in...